Merus N.V. (MRUS)
undefined
undefined%
At close: undefined
42.83
0.07%
After-hours Dec 13, 2024, 04:00 PM EST

Company Description

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands.

Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.

The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma.

In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145.

The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Merus N.V.
Merus N.V. logo
Country NL
IPO Date May 19, 2016
Industry Biotechnology
Sector Healthcare
Employees 172
CEO Dr. Sven Ante Lundberg M.D.

Contact Details

Address:
Yalelaan 62
Utrecht,
NL
Website https://www.merus.nl

Stock Details

Ticker Symbol MRUS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001651311
CUSIP Number N5749R100
ISIN Number NL0011606264
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Dr. Sven Ante Lundberg M.D. Chief Executive Officer, President & Executive Director
Audrey Bergan Chief People Officer
Cornelis Adriaan de Kruif Ph.D. Chief Technology Officer & Executive Vice President
Gregory D. Perry Chief Financial Officer
Peter B. Silverman J.D. EVice President, Company Secretary, Chief Operating Officer, General Counsel, Chief Intellectual Property Officer & Head of US Legal
Dr. Cecilia Anna Wilhelmina Geuijen Ph.D. Chief Scientific Officer & Senior Vice President
Dr. Hennie Hoogenboom Co-Founder and Scientific Advisor
Harry Shuman Chief Accounting Officer
Kathleen Farren IR & Corporate Communications Officer
Shannon Campbell Executive Vice President & Chief Commercial Officer

Latest SEC Filings

Date Type Title
Dec 05, 2024 8-K Current Report
Dec 02, 2024 8-K Current Report
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 14, 2024 SC 13G Statement of acquisition of beneficial ownership b...
Nov 12, 2024 SC 13G Statement of acquisition of beneficial ownership b...
Nov 05, 2024 8-K Current Report
Oct 31, 2024 10-Q Quarterly Report
Aug 22, 2024 4 Filing